Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-15
2005-02-15
Chang, Ceila (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C435S001100, C435S012000, C436S057000, C436S098000, C436S124000, C436S905000
Reexamination Certificate
active
06855828
ABSTRACT:
Nitroaromatic compounds and immunogenic conjugates comprising a novel nitroaromatic compound and a carrier protein are disclosed. The invention further presents monoclonal antibodies highly specific for the claimed nitroaromatic compounds, the compounds' protein conjugates, the compounds' reductive byproducts, and adducts formed between the compounds and mammalian hypoxic cell tissue proteins. The invention is further directed to methods for detecting tissue hypoxia using immunohistological techniques, non-invasive nuclear medicinal methods, or nuclear magnetic resonance. Diagnostic kits useful in practicing the methods of claimed invention are also provided.
REFERENCES:
patent: 3505349 (1970-04-01), Beaman et al.
patent: 3679698 (1972-07-01), Beaman et al.
patent: 4241060 (1980-12-01), Smithen
patent: 4371540 (1983-02-01), Lee et al.
patent: 4797397 (1989-01-01), Suto et al.
patent: 4816401 (1989-03-01), Taupier et al.
patent: 4927941 (1990-05-01), Kagiya et al.
patent: 4977273 (1990-12-01), Kagiya et al.
patent: 5030036 (1991-07-01), Huff et al.
patent: 5086068 (1992-02-01), Raleigh et al.
patent: 5304654 (1994-04-01), Kagiya et al.
patent: 5540908 (1996-07-01), Koch et al.
patent: 5721265 (1998-02-01), Tracy et al.
patent: 5843404 (1998-12-01), Koch et al.
patent: WO 0112575 (2001-02-01), None
Adams, “Hypoxia-Mediated Drugs for Radiation and Chemotherapy”,Cancer, 1981, 48, 696-707.
Beaman et al., “Studies in the nitromidazole series. III. 2-Nitro-imidiazole dderivatives substituted in the 1-position”, Chemical Abstract 71(5): 22065t, 1967, p. 22060.
Chapman et al., “The Fraction of Hypoxic Clonogenic Cells in Tumor Populations”,Biol. Bases Clin. Imp. Tum. Rad., G.H. Fletcher, C. Nevil, & H.R. Withers, (eds.), 1983, 61-73.
Chapman et al., “Keynote Address: Cellular Reduction of Nitroimidazole Drugs: Potential for Selective Chemotherapy and Diagnosis of Hypoxic Cells”,Int. J. Radiation Oncol. Biol. Phys., 1989, 16, 911-917.
Franko et al., “Oxygen Supply to Spheroids in Spinner and Liquid-Overlay Culture”, Recent Results inCancer Res. in 94″ Culture of Cellular Spheroids 62, 1984, 95, 162-167.
Grunberg et al., “Antiprotozoan and antibacterial activity of 2-nitro-imidazole derivatives”, Chemical Abstract 70(3):10175v, 1968, p. 10174.
Heindel et al, “Macromolecular Attachment as a Metabolic Stabilizer for a Labile Radiosensitizer”,J. Pharm. Sci., 1987, 76(5), 384-386.
Kohler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”,Nature, 1975, 256, 495-497.
Knauf et al., “Monoclonal antibodies against human ovarian tumor asociated antigen NB/70K: Preparation and use in a radioimmunoassay for measuring NB/70K in serum”,Cancer Immunol. Immunother., 1986, 21, 217-225.
Raleigh et al., “Reductive Fragmentation of 2-Nitroimidazoles: Amines and Aldehydes”,Int. J. Radiation Oncol. Biol. Phys., 1984, 10, 1337-1340.
Raleigh et al., “Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours,”Br. J. Cancer, 1987, 56, 395-400.
Taylor et al., “Differences in the toxicity and Metabolism of the 2-Nitroimidazole Misonidazole (Ro-07-0582) in HeLa and Chinese Hamster Ovary Cells”,Cancer Res., 1978, 38, 2745-2752.
Urtasun et al., “A novel technique for measuring human tissue pO2at the cellular level”,Br. J. Cancer, 1986, 54, 453-457.
Varghese et al., “Binding to Cellular Macromolecules as a Possible Mechanism for the Cytotoxicity of Misonidazole”,Cancer Res., 1980, 40, 2165-2169.
Lord, et al.,“Detection of Hypoxic Cells by Monoclonal Antibody Recognizing 2-Nitroimidazole Adducts”,Cancer Res., 1993, 53, 5721-5726.
Franko, A.J. et al., “Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro”,Cancer Res., 1987, 47, 5367-5376.
Harwell et al.,J. Immunol. Methods, 1984, 66, 59-67.
Kennedy et al.,Biochem. Pharm., 1980, 29, 1-8.
Koch, C.J., “A thin-film culturing technique allowing rapid gas-liquid equilibration (6 seconds) with no toxicity to mammalian cells”,Radiat. Res., 1984, 97, 434-442.
Koch, C.J. et al., “Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration an dmisonidazole concentration”,Int. J. Radiation Oncology Biol. Phys., 1984, 10, 1327-1332.
Koch, C.J. et al., “Radiolytic Reduction of Protein and Nonprotien Disulfides in the Presence of Formate: A Chain Reaction”,Arch. Biochem. Biophys., 1991, 287, 75-84.
Moulder, J.E. et al., “Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data”,Int. J. Radioat. Oncol. Biol. Phys. 1984, 10, 695-712.
Parliament et al., “Non-invasive assessment of human tumour hypoxia with123I-iodoazomycin arabinoside: preliminary report of a clinical study”,Br. J. Cancer, 1992, 65, 90-95.
Rasey et al., “Characterization of Radiolabeled Fluoromisonidazole as a Probe for Hypoxic Cells”,Radiation Res., 1987, 111, 292-304.
Koch, C.J., “The reductive activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems”,Selective Activation of Drugs by Redox Processes, 1990,NATO Series A 198, 237-247.
Arteel, GE et al., “Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver”,British J. Cancer, 1995, 72(4), 889-895.
Raleigh et al., “Importance Of Thiols In The Reductive Binding of 2-Nitroimidazoles to Macromolecules”,Biochem. Pharmacol., 1990, 40, 2457-2464.
Tewson, T.J., “Synthesis of [18F] Fluoroetanidazole: a potential new tracer for imaging hypoxia”,Nucl. Med. Biol., 1997, 24(8), 755-760.
Hamacher et al., “Efficient Stereospecific Synthesis of No-Carrier-Added 2-[18F]-Fluoro-2-Deoxy-D-Glucose Using Aminopolyether Supported Nucleophilic Substitution”,J. Nucl. Med., 1986, 27(2), 235-238.
Adams, G.E., “Selective Activation of Drugs by Redox Processes”,NATO Series A 198, 1990.
Bialik, S. et al., “Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53”,J. Clin. Investig., 1997, 100, 1363-1372.
Brizel, D.M. et al., “Tissue oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma”,Cancer Res., 1996, 56, 941-943.
Brizel, D.M. et al., “Pretreatment oxygenation profiles of human soft tissue sarcomas”,Int. J. Radiat. Oncol. Biol. Phys., 1994, 30, 635-642.
Brizel, D.M. et al., “Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck”,Int. J. Radiat. Oncol. Biol. Phys.,1997, 38, 285-289.
Brown, J.M. et al., “SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use”,Int. J. Radiat. Oncol. Biol. Phys., 1981, 7, 695-703.
Cater, D.B. et al., “Quantitative meaurements of oxygen tensions in normal tissues and in the tumors of patients before and after radiotherapy”,Acta. Radiol., 1960, 23, 233-256.
Chapman, J.D. et al., “Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells”,Cancer Res., 1983, 45, 1523-1528.
Clyman, R.I. et al., “Permanent anaotomic closure of the newborn ductus arteriosus: the roles of postnatal constriction, hypoxia and gestation”, New Eng. J. Med., Submitted, 1997.
Cobb, L.M. et al., “Microscopic distribution of misonidazole in mouse tissues”,Br. J. Cancer, 1989, 59, 12-16.
Cobb, L.M. et al., “Retention of misonidazole in normal and malignant tissues: interplay of hypoxia and reductases”,Int. J. Rad. Onc. Biol. Phys., 19982, 22, 655-659.
Coleman, C.N. et al., “Relationship between the neurotoxicity of the hypoxic cell radi
Baird Ian R.
Dolbier, Jr. William R.
Evans Sydney M.
James Brian R.
Kachur Alexander V.
Chang Ceila
Woodcock & Washburn LLP
Wright Sonya
LandOfFree
Detection of hypoxia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of hypoxia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of hypoxia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3487323